About Aria Pharmaceuticals
Aria Pharmaceuticals is a company based in Palo Alto (United States) founded in 2015 by Andrew Radin. It operates as a B2B. Aria Pharmaceuticals has raised $14.31 million across 3 funding rounds from investors including Andreessen Horowitz, OS Fund and SBVA. Aria Pharmaceuticals operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Palo Alto, United States
- Founders Andrew Radin
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Twoxar, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.31 M (USD)
in 3 rounds
-
Latest Funding Round
$1.14 M (USD), Post-IPO
Jul 26, 2019
-
Investors
Andreessen Horowitz
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Aria Pharmaceuticals
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Aria Pharmaceuticals
Aria Pharmaceuticals has successfully raised a total of $14.31M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.14 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aria Pharmaceuticals
Aria Pharmaceuticals has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Andreessen Horowitz, OS Fund and SBVA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Early-stage centric sector-agnostic VC firm investing in geographies such as the US
|
Locked | Locked | Locked | |
|
Early-stage venture capital arm of SoftBank Group
|
Locked | Locked | Locked |
Investor details for Aria Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aria Pharmaceuticals
Investment portfolio details for Aria Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aria Pharmaceuticals
Detailed financials for Aria Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aria Pharmaceuticals Comparisons
Peer comparison for Aria Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aria Pharmaceuticals
Aria Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Aria Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aria Pharmaceuticals
Complete news archive for Aria Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aria Pharmaceuticals
Aria Pharmaceuticals was founded in 2015.
Aria Pharmaceuticals is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Aria Pharmaceuticals is a funded company, having raised a total of $14.31M across 3 funding rounds to date.
Aria Pharmaceuticals operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, drug development, and innovative technologies. Develops innovative drug technologies for multiple diseases. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Aria Pharmaceuticals's top competitors include Moderna, argenx and Forge Biologics.
Aria Pharmaceuticals has 5 investors. Key investors include Andreessen Horowitz, OS Fund, SBVA, CLI Ventures, and StartX.